Literature DB >> 10691197

Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.

C M Gerber1, M Cottagnoud, K A Neftel, M G Täuber, P Cottagnoud.   

Abstract

In a rabbit model of meningitis caused by a pneumococcus highly resistant to penicillin (MIC, 4 microg/ml), meropenem, a broad-spectrum carbapenem, was bactericidal (-0.48+/-0.14 deltalog10 cfu/ml h) and slightly superior to ceftriaxone (-0.34+/-0.23 deltalog10 cfu/ml x h) and vancomycin (-0.39+/-0.19 deltalog10 cfu/ml x h). Although the combination of vancomycin with ceftriaxone was significantly more active than ceftriaxone alone (-0.55+/-0.19 deltalog10 cfu/ml x h), only an insignificant gain was observed by the addition of vancomycin to meropenem (-0.55+/-0.28 deltalog10 cfu/ml x h).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10691197     DOI: 10.1007/s100960050421

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.

Authors:  P Cottagnoud; F Acosta; M Cottagnoud; K Neftel; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.

Authors:  Armin Stucki; Peter Gerber; Fernando Acosta; Marianne Cottagnoud; Philippe Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant streptococcus pneumoniae in an experimental rabbit meningitis model.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; A Stucki
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

4.  Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Domenech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04-02       Impact factor: 3.267

5.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

6.  Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Doménech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-17       Impact factor: 3.267

7.  Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.

Authors:  P Cottagnoud; M Pfister; M Cottagnoud; F Acosta; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

8.  Meropenem versus Cefotaxime and Ampicillin as Empirical Antibiotic Treatment in Adult Bacterial Meningitis: a Quality Registry Study, 2008 to 2016.

Authors:  Magnus Brink; Martin Glimåker; Jan Sjölin; Pontus Naucler
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

9.  Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis.

Authors:  Shin-Woo Kim; Joung Hwa Jin; Soo Jung Kang; Sook-In Jung; Yeon-Sook Kim; Choon-Kwan Kim; Hyuck Lee; Won Sup Oh; Sungmin Kim; Kyong Ran Peck; Jae-Hoon Song
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.